Drug major Sun Pharma today said it has received approval from the US health regulator for generic version of anti-allergic product Prometh syrup.
The United States Food and Drug Administration (FDA) has granted an approval to the company's subsidiary for the syrup, Sun Pharmaceutical Industries Ltd said in a statement to the Bombay Stock Exchange.
The company's product--Promethazine Hydrochloride and Codeine Phosphate Oral Syrup--is bioequivalent to Prometh. It has annual sales of about $16 million in the US.
The medicine is used to treat symptoms caused by common cold, flu, allergies or other breathing problems.
Shares of Sun Pharma were quoting at Rs 1,697.80, up by 0.19 per cent in the afternoon trade on the BSE.
